The fundamental unit of biology is a molecule. For genomics, the ability to read DNA one base at a time, at scale, unlocked a new era of discovery. Proteomics, the study of proteins, has been stuck with bulk measurements. Erisyon, a spinout from the University of Texas at Austin, is betting that bringing single-molecule, massively parallel sequencing to proteins will do the same for understanding disease [Genetic Engineering & Biotechnology News, August 2023].
Its platform, based on a technique called fluorosequencing, is designed to sequence individual protein molecules and quantify their abundance directly from complex biological samples [Genetic Engineering & Biotechnology News, August 2023]. The company calls it the world's first single-molecule protein sequencer, a claim that underscores both the ambition of the technical leap and the nascency of the field it aims to define [LinkedIn].
The technical wedge: fluorosequencing
Erisyon's core innovation is an architectural one, applying a principle proven in next-generation DNA sequencing to the far more complex world of proteins. The method, invented in the labs of UT Austin professors Eric Anslyn and Edward Marcotte, involves labeling individual amino acids within a protein with fluorescent tags, immobilizing the molecules on a surface, and then reading the fluorescent signals as they are sequentially cleaved [Erisyon].
This approach promises several key advantages over existing mass spectrometry-based proteomics.
- Single-molecule sensitivity. The platform aims to detect and count individual protein molecules, moving beyond the averaged signals of bulk analysis. This could reveal rare protein variants or low-abundance biomarkers hidden in heterogeneous tissue samples [Erisyon].
- Digital quantification. Each molecule counted is a discrete digital readout, enabling absolute quantification of protein copy numbers rather than relative abundance. This is a critical step toward standardized, reproducible assays [Erisyon].
- Massively parallel throughput. The company's architecture is designed for billions of simultaneous experiments on a single chip, a necessity for making the technology practical for research and eventual clinical use [Erisyon].
The company has already open-sourced a key component of its software stack. Its fluorosequencing data analysis package, plaster SigProc, is available on GitHub, suggesting a focus on building tools and community around the raw data its hardware will generate [PLOS Computational Biology, 2024].
A founding team built for the long haul
Erisyon's structure is a classic deep-tech blueprint: foundational academic research paired with commercial execution. The co-founding team is led by six individuals, each bringing a distinct piece of the puzzle [Genetic Engineering & Biotechnology News, August 2023].
| Role | Founder | Primary Contribution |
|---|---|---|
| CEO & Commercial Lead | Talli Somekh | Entrepreneurial and commercial strategy |
| Scientific Founder | Jagannath "Jag" Swaminathan | UT Austin research scientist |
| Scientific Founder | Edward Marcotte | UT Austin professor, 20+ years in proteomics & bioinformatics [Research Bridge Partners] |
| Scientific Founder | Eric Anslyn | UT Austin professor of chemistry |
| Scientific Founder | Angela Bardo | UT Austin research scientist |
| Technologist Founder | Zack Simpson | Outside technologist and former VP of Informatics (2018-2022) |
This blend is deliberate. Marcotte and Anslyn provide the deep scientific credibility and IP foundation, with Marcotte alone authoring over 200 articles and holding 16 patents [Research Bridge Partners]. Somekh, the son of Musea Ventures founder Sass Somekh, leads the commercial push [The Mercury News, December 2009]. The company has also leveraged connections to secure non-dilutive funding, with key personnel like Yifat Merbl and Jianjun Zhang credited with helping to secure grants [LinkedIn].
Fueled by non-dilutive capital
Erisyon's funding story is less about venture rounds and more about strategic, milestone-driven grants. This is common for hardware-based life science tools where validating the core science is a prerequisite for large-scale commercial investment. The company has secured over $4.4 million in non-dilutive funding from government and philanthropic organizations focused on specific disease applications.
Michael J. Fox Foundation Grant (May 2020) | 0.18872 | M USD
CPRIT Grant (Jan 2025) | 2.2 | M USD
CPRIT Grant (Unknown Date) | 2.2 | M USD
A $188,720 grant from the Michael J. Fox Foundation in May 2020 was explicitly for validating methods to detect biomarkers for early Parkinson's disease [Technology Networks, May 2020]. The two grants from the Cancer Prevention and Research Institute of Texas (CPRIT), totaling $4.4 million, signal a focus on oncology applications [Yahoo Finance, January 2025]. These grants are not just capital; they are validation from experts who have defined the problem Erisyon aims to solve.
A seed investment from Research Bridge Partners in November 2020 provided undisclosed capital to fund core platform technology and IP development, but the grant-heavy cap table reveals a capital-efficient, proof-of-concept-first strategy [Research Bridge Partners, November 2020].
The path to a product
Publicly, Erisyon is still in the development and validation phase. The company is engaging in collaborative research projects to translate its single-molecule methods into tangible biomarker discovery and validation workflows [MTEC]. Its stated initial market includes life-science researchers, biotech and pharmaceutical companies, and diagnostic-development groups,all entities that would integrate a new tool into an existing R&D pipeline, not replace an entire infrastructure [leadiq.com].
The technical breakdown is promising, but it highlights the scale of the challenge. Fluorosequencing generates an enormous, novel data type. Building the computational pipelines to analyze it reliably, and the wet-lab protocols to prepare samples for it consistently, is a software and systems integration problem as large as the hardware one. The open-source release of plaster SigProc is a smart first step toward building that ecosystem.
The sober assessment is that biology is messy. Proteins are modified, folded, and exist in complexes that could confound a sequencing-by-synthesis approach designed for linear polymers. Scaling from a research prototype to a reproducible, user-friendly instrument that can be operated by a lab technician,and doing so at a cost that makes single-molecule proteomics accessible,is a multi-year engineering marathon. The grants validate the scientific premise, but they don't guarantee a smooth production ramp.
Erisyon's bet is that the bottleneck in understanding complex diseases is no longer the ability to read genes, but the ability to read their functional products with equal precision. If it can ship a reliable instrument and the software to make its data usable, it won't just be selling a sequencer. It will be selling a new lens for biology.
Sources
- [Genetic Engineering & Biotechnology News, August 2023] Protein Sequencing Expands the Omics Club | https://www.genengnews.com/topics/drug-discovery/protein-sequencing-expands-the-omics-club/
- [LinkedIn] Erisyon | LinkedIn | https://www.linkedin.com/company/erisyon
- [Erisyon] Erisyon Company Website | https://www.erisyon.com/
- [PLOS Computational Biology, 2024] PLOS Computational Biology article on plaster SigProc | https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1011743
- [Research Bridge Partners, November 2020] Research Bridge Partners Makes Seed Capital Investment in Erisyon Inc. | https://www.researchbridgepartners.org/research-bridge-partners-makes-seed-capital-investment-in-erisyon-inc/
- [The Mercury News, December 2009] Mercury News interview: Sass Somekh, founder of Musea Ventures | https://www.mercurynews.com/2009/12/11/mercury-news-interview-sass-somekh-founder-of-musea-ventures/
- [Technology Networks, May 2020] Erisyon Awarded Michael J. Fox Foundation Grant To Validate Methods for Early Parkinson’s Detection | https://www.technologynetworks.com/cancer-research/product-news/erisyon-awarded-michael-j-fox-foundation-grant-to-validate-methods-for-early-parkinsons-detection-334527
- [Yahoo Finance, January 2025] Yahoo Finance article on CPRIT grant | https://finance.yahoo.com/news/cancer-prevention-research-institute-texas-120000345.html
- [MTEC] MTEC collaborative research listing | https://www.mtec-sc.org/portfolio-item/erisyon/
- [leadiq.com] Erisyon company profile on leadiq.com | https://leadiq.com/c/erisyon/5ed241c78a998f161e369640